We are delighted to extend our congratulations to Tomas Paulenda and Prof. Maxim Artyomov at Washington University in St. Louis on the recent publication of their work in Nature Metabolism.
We would also like to recognize the significant contributions of Dr. Johannes Mehringer from the KSI Institute, whose expertise in biophysical analysis played a central role in uncovering the molecular interaction between itaconate and peroxiredoxin 5 (PRDX5).
Key Findings
The study sheds light on how itaconate, a naturally occurring metabolite produced by immune cells during inflammation, influences immune responses. The research demonstrates that by binding to PRDX5, itaconate can:
-
Enhance protective type I interferons
-
Limit excessive inflammation
-
Modulate cellular handling of reactive oxygen species
Why This Matters
These results provide important new insights into the body’s intrinsic mechanisms for regulating inflammation. By identifying how itaconate interacts with PRDX5, the study opens potential avenues for developing novel therapies for inflammatory diseases.
We look forward to further advancing our understanding of molecular immunology through collaborative research.
The full article is available in → Nature Metabolism.